Browsing category:

Synthetic Peptide


Known as the brand name Byetta in the United States, which is marketed by AstraZeneca, Exenatide is a GLP-1 analog that is currently offered as an injectable treatment for type 2 diabetes. In mid-January 2015 Oramed Pharmaceuticals was granted a patent in Israel for the oral administration of Exenatide. As an effectual therapy for patients[…]

Read More

Used to regulate hormone responses in female patients undergoing infertility treatment, Cetrorelix, is also known as the brand name Cetrotide. On April 17, 2013 Aeterna Zentaris announced the transfer of the manufacturing rights of this powerhouse product to Merck Serono. With the patent for Cetrotide set to expire on April 23, 2019, this transfer of[…]

Read More